US SB3872 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Republican 8-0)
Status: Introduced on June 3 2020 - 25% progression, died in committee
Action: 2020-06-03 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on June 3 2020 - 25% progression, died in committee
Action: 2020-06-03 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Establishes a provisional approval pathway for medicines intended for serious or life-threatening diseases, including illnesses posing a threat of epidemic or pandemic. The period of the provisional approval is for two years and is potentially renewable. The Food and Drug Administration (FDA) must establish a priority review system to evaluate completed provisional approval applications within 90 days of receipt. A provisional approval application may be approved if the FDA determines that (1) there is substantial evidence of safety for the drug; and (2) there is relevant early evidence of efficacy, based on adequate and well-controlled investigations. During the COVID-19 (i.e., coronavirus disease 2019) pandemic, or another epidemic or pandemic, the FDA must accept and review various portions of a provisional approval application on a rolling basis. The manufacturer of a provisionally approved drug must require patients to participate in an observational registry. A manufacturer that fails to comply with registry requirements is subject to civil penalties. A provisionally approved drug must be labeled as such. If a drug that receives provisional approval status is not brought to market within 180 days of the approval, the approval must be rescinded. The bill also limits the liability of a manufacturer of a provisionally approved drug with respect to any claim under state law alleging that the drug is unsafe or ineffective. Private health insurers and federal health care programs shall not deny coverage of a provisionally approved drug on the basis of it being experimental.
Title
Promising Pathway Act
Sponsors
Sen. Mike Braun [R-IN] | Sen. Lisa Murkowski [R-AK] | Sen. Martha McSally [R-AZ] | Sen. Susan Collins [R-ME] |
Sen. Kevin Cramer [R-ND] | Sen. John Boozman [R-AR] | Sen. David Perdue [R-GA] | Sen. Roger Wicker [R-MS] |
History
Date | Chamber | Action |
---|---|---|
2020-06-03 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB7269 (Same As) 2020-06-18 - Referred to the House Committee on Energy and Commerce.
Subjects
Cardiovascular and respiratory health
Civil actions and liability
Congressional oversight
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Employee benefits and pensions
Government information and archives
Government studies and investigations
Health
Health care costs and insurance
Health care coverage and access
Health information and medical records
Immunology and vaccination
Infectious and parasitic diseases
Licensing and registrations
Manufacturing
Medical research
Medical tests and diagnostic methods
Prescription drugs
Scientific communication
Civil actions and liability
Congressional oversight
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Employee benefits and pensions
Government information and archives
Government studies and investigations
Health
Health care costs and insurance
Health care coverage and access
Health information and medical records
Immunology and vaccination
Infectious and parasitic diseases
Licensing and registrations
Manufacturing
Medical research
Medical tests and diagnostic methods
Prescription drugs
Scientific communication
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/senate-bill/3872/all-info |
Text | https://www.congress.gov/116/bills/s3872/BILLS-116s3872is.pdf |